Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Psoriatic Arthritis
NCT00534313Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2007
- Primary completion
- Dec 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 2 trial of abatacept in psoriatic arthritis (PsA), sponsored by Bristol Myers Squibb. Started Nov 2007; status: terminated.
02
Drugs
abatacept
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00534313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00534313.